How Adoptive Cell Therapy Works
Our technology is based on TIL isolated from the patient’s tumor following resection. The cells are then expanded to billions in vitro, away from cancer’s immune-suppressing effects. These highly activated, potent TIL are then infused back into the patient, who has been preconditioned to remove all suppressive influences.
NOW ENROLLING
Current Clinical Trials
PHYSICIANS: To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts.
C-145-03: Squamous Cell Carcinoma of the Head and Neck (HNSCC)
A Phase 2, Multicenter Study to Assess the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (LN-145) for Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
View
C-145-04: Cervical Carcinoma
A Phase 2, Multicenter study to Assess the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (LN-145) for Treatment of Patients with Cervical Carcinoma.
View
IOV-LUN-201: Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and in Combination with Anti-PD-L1 Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
View
IOV-COM-202: Immunotherapy For Solid Tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN‑144 or LN-145) in Patients with Solid Tumors.
View